Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The Preclinical Activities of PTC596, a Novel Tubulin Binding Agent That Down-Regulates BMI1, Alone and in Combination with Bortezomib in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 4414.

https://doi.org/10.1182/blood-2019-122350

Published: 2019

Journal Articles

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

Tengteng Yu, MD PhD, Liang Lin, PhD, Kenneth Wen, Lijie Xing, MD, Jiye Liu, PhD, Shih-Feng Cho, MD PhD, Phillip Hsieh, Ola Rizq, MD PhD, Yuyin Li, PhD, Liang Yu, Xiang Wu, Eugenio Morelli, MD, Yan Xu, MD, Gang An, MD, Nikhil C. Munshi, MD, Lugui Qiu, MD PhD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 4371.

https://doi.org/10.1182/blood-2019-127454

Published: 2019

Journal Articles

Akt Inhibition Differently Controls PRC2 Components and Synergizes with Dual EZH2/1 Inhibitor in the Treatment of Multiple Myeloma

Mohamed Rizk, BSc, MSc, Ola Rizq, MD PhD, Motohiko Oshima, PhD, Yaeko Nakajima-Takagi, PhD, Shuhei Koide, PhD, Atsunori Saraya, Yusuke Isshiki, MD PhD, Tetsuhiro Chiba, MD PhD, Satoshi Yamazaki, PhD, Anqi Ma, PhD, Jian Jin, PhD, Atsushi Iwama, MD PhD, Naoya Mimura, MD PhD

Blood (2019) 134 (Supplement_1): 4400.

https://doi.org/10.1182/blood-2019-122157

Published: 2019

Journal Articles

Utx Insufficiency Cooperates with Braf V600E in the Induction of Myeloma in Mice

Ola Rizq, MD PhD, Naoya Mimura, MD PhD, Motohiko Oshima, PhD, Shuji Momose, MD PhD, Yaeko Nakajima-Takagi, PhD, Kazumasa Aoyama, PhD, Atsunori Saraya, Tohru Iseki, MD PhD, Emiko Sakaida, MD PhD, Chiaki Nakaseko, MDPhD, Yutaka Okuno, MD, PhD, Hiroaki Honda, MD PhD, Jun-ichi Tamaru, MDPhD, Atsushi Iwama, MD PhD

Blood (2018) 132 (Supplement 1): 1005.

https://doi.org/10.1182/blood-2018-99-114053

Published: 2018

Journal Articles

Molecular Mechanism behind the Synergistic Activity of Proteasome Inhibition and PRC2 Inhibition in the Treatment of Multiple Myeloma

Ola Rizq, MD, Naoya Mimura, MD PhD, Motohiko Oshima, PhD, Atsunori Saraya, Shuhei Koide, PhD, Yuko Kato, PhD, Kazumasa Aoyama, PhD, Yaeko Nakajima-Takagi, PhD, Changshan Wang, PhD, Anqi Ma, Jian Jin, PhD, Tohru Iseki, MD PhD, Chiaki Nakaseko, MD, PhD, Atsushi Iwama, MD PhD

Blood (2016) 128 (22): 312.

https://doi.org/10.1182/blood.V128.22.312.312

Published: 2016

NARROW

The Preclinical Activities of PTC596, a Novel Tubulin Binding Agent That Down-Regulates BMI1, Alone and in Combination with Bortezomib in Multiple Myeloma

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

Akt Inhibition Differently Controls PRC2 Components and Synergizes with Dual EZH2/1 Inhibitor in the Treatment of Multiple Myeloma

Utx Insufficiency Cooperates with Braf V600E in the Induction of Myeloma in Mice

Molecular Mechanism behind the Synergistic Activity of Proteasome Inhibition and PRC2 Inhibition in the Treatment of Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

The Preclinical Activities of PTC596, a Novel Tubulin Binding Agent That Down-Regulates BMI1, Alone and in Combination with Bortezomib in Multiple Myeloma

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

Akt Inhibition Differently Controls PRC2 Components and Synergizes with Dual EZH2/1 Inhibitor in the Treatment of Multiple Myeloma

Utx Insufficiency Cooperates with Braf V600E in the Induction of Myeloma in Mice

Molecular Mechanism behind the Synergistic Activity of Proteasome Inhibition and PRC2 Inhibition in the Treatment of Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only